Abstract: We provide new monoclonal antibody inhibitors of coagulases staphylocoagulase and vWbp for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the coagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases staphylocoagulase and vWbp for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus of SC and vWbp (respectively) and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the coagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting SC-ProT activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting SC-ProT activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting SC-ProT activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting SC-ProT activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: We provide new monoclonal antibody inhibitors of coagulases for treatment of S. aureus. The monoclonal antibodies are useful in targeting the SC N-terminus and inhibiting prothrombin activation. The monoclonal antibodies are able to bind to and interfere with, modulate, and/or inhibit the binding interactions between the staphylocoagulase protein and its ligand protein prothrombin in blood and tissues. The antibodies are effective in inhibiting the activation of prothrombin.

Abstract: Methods and products for the treatment of a disorder characterized by the cleavage of a C-terminal lysine or arginine from an intact peptide are provided. In the methods of the invention a peptide that inhibits the activation of thrombin-activatable fibrinolysis inhibitor (TAFI) is administered in an effective amount and in a pharmaceutically acceptable carrier to a subject having a disorder characterized by the cleavage of a C-terminal lysine or arginine from an intact peptide. The compositions are pharmaceutical compositions of peptides that inhibit the activation of TAFI. Also provided is a monoclonal antibody that binds TAFI zymogen but that does not bind to active TAFI and inhibits the activation of TAFI.